ArticleMolecular biology reports2026
Transcriptional activation of Carbonic Anhydrase III (CAIII) mediated by SP1.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarbonic anhydrase III (CAIII) is among the least characterized carbonic anhydrase isoforms, particularly in cancer. Although CAIII has been suggested to contribute to cellular antioxidant defense due to its high cysteine content, limited data exist regarding its expression patterns and transcriptional regulation in malignancies. Previous studies have shown that CAIII can be regulated by hypoxia and signaling pathways such as PI3K and MAPK/ERK; however, its regulation under normoxic conditions remains largely unknown. METHODS AND
resultsHere, we investigated the transcriptional regulation of the human CAIII gene. In silico analysis demonstrated high sequence conservation within the proximal promoter region of CAIII among human, mouse, and rat, and no CpG island was detected. Promoter deletion assays identified the − 236 to + 86 region as the core active promoter, which contains multiple SP1 binding sites. Overexpression of SP1 significantly increased CAIII mRNA and protein levels. Transient transfection assays further confirmed that SP1 enhances the activity of CAIII promoter constructs. Electrophoretic mobility shift assays demonstrated direct binding of SP1 to the CAIII promoter, while mutation of SP1 binding elements abolished DNA–protein complex formation, confirming the specificity of this interaction.
conclusionsThis study provides the first detailed characterization of the human CAIII promoter and identifies SP1 as a critical transcriptional regulator of CAIII through direct promoter binding. These findings provide new insights into the molecular regulation of CAIII and establish a foundation for future studies exploring its biological and pathological roles.
Indexed as
Identifiers
41824129What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.